UPB

Upstream Bio, Inc.

Investor Moves

NameValueActionChangePriceLast Price
Steven CohenPoint72
$2M189.7k shares
AddQ1 2026
$1M
$9.00
$7.01
Ken GriffinCitadel Advisors
$707k78.5k shares
AddQ1 2026
$71k
$9.00
$7.01
Jim SimonsRenaissance Technologies
$559k62.1k shares
AddQ1 2026
$114k
$9.00
$7.01
Ken GriffinCitadel Advisors
$-252.0K
TrimQ4 2025
$252k
--
$7.01
Ken GriffinCitadel Advisors
$-3.0M
ExitQ1 2025
$3M
--
$7.01
George SorosSoros Fund Management
$-762.0K
ExitQ1 2025
$762k
--
$7.01

Insider Trades

NameValueActionPriceLast Price
Ambrose AllisonGeneral Counsel
$4.4k475 shares
SellMar 16, 2026
$9.29
$7.01
Sutherland Everett RandDirector, Officer: Chief Executive Officer
$19k2.1k shares
SellMar 16, 2026
$9.29
$7.01
Deykin AaronChief Medical Officer
$8.3k894 shares
SellMar 16, 2026
$9.29
$7.01
Gray MichaelCFO And COO
$7.9k852 shares
SellMar 16, 2026
$9.29
$7.01
Houghton AdamChief Business Officer
$6.5k699 shares
SellMar 16, 2026
$9.29
$7.01

News

seekingalpha.comUpstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 10globenewswire.comUpstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026globenewswire.comJun 8globenewswire.comUpstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conferenceglobenewswire.comJun 3seekingalpha.comUpstream Bio: The Reset Is The Opportunity, Initiating At Buyseekingalpha.comMay 29globenewswire.comUpstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conferenceglobenewswire.comMay 18